Table 2.

Univariate and multivariate analyses of DFS and OS in all patients

		DFS						OS
Factors	N (%)	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
		HR 95% CI P			HR 95% CI P			HR 95% CI P			HR 95% CI P
Gender
Male	106 (44.0%)	1.0 (ref)			1.0 (ref)			1.0 (ref)			1.0 (ref)
Female	135 (56.0%)	0.64	0.46–0.90	0.011	0.79	0.51–1.23	0.300	0.62	0.40–0.97	0.036	0.77	0.45–1.34	0.361
Age (years)
≤ 56	118 (49.0%)	1.0 (ref)						1.0 (ref)
> 56	123 (51.0%)	0.97	0.69–1.37	0.871				1.02	0.65–1.58	0.946
Smoking history
Never	145 (60.2%)	1.0 (ref)			1.0 (ref)			1.0 (ref)			1.0 (ref)
Current/former	96 (39.8%)	1.57	1.12–2.22	0.010	1.00	0.62–1.62	0.994	1.81	1.16–2.81	0.009	0.87	0.48–1.57	0.635
Histology
Adenocarcinoma	229 (95.0%)	1.0 (ref)						1.0 (ref)
Non‐Adenocarcinoma	12 (5.0%)	1.41	0.66–3.03	0.373				1.84	0.80–4.23	0.152
p stage
I/II	128 (35.7%)	1.0 (ref)			1.0 (ref)			1.0 (ref)			1.0 (ref)
III	113 (64.3%)	3.87	2.67–5.61	< 0.001	3.87	2.66–5.64	< 0.001	2.87	1.79–4.62	< 0.001	2.72	1.68–4.42	< 0.001
EGFR status
Wild‐type	162 (67.2%)	1.0 (ref)						1.0 (ref)			1.0 (ref)
Mutated	79 (32.8%)	0.70	0.48–1.02	0.065				0.53	0.31–0.92	< 0.001	0.48	0.25–0.91	0.026
KRAS status
Wild‐type	218 (90.5%)	1.0 (ref)						1.0 (ref)			1.0 (ref)
Mutated	23 (9.5%)	1.54	0.90–2.65	0.114				2.66	1.35–5.21	< 0.001	1.88	1.03–3.43	0.040
PD‐L1 status
< 50%	206 (85.5%)	1.0 (ref)			1.0 (ref)			1.0 (ref)			1.0 (ref)
≥ 50%	35 (14.5%)	2.13	1.39–3.26	0.001	2.55	1.56–4.18	< 0.001	2.37	1.24–4.54	< 0.001	3.07	1.73–5.45	< 0.001

DFS, disease‐free survival; OS, overall survival; HR, hazard ratio; ref., reference category; TPS, tumor proportion score.